Denu et al., 2023 - Google Patents
The landscape of alterations from 1407 ultra-rare sarcomas from the AACR GENIE database: Clinical implicationsDenu et al., 2023
- Document ID
- 126931922296118084
- Author
- Denu R
- Moyers J
- Gouda M
- Conley A
- Lazar A
- Subbiah V
- Publication year
- Publication venue
- Clinical Cancer Research
External Links
Snippet
Purpose: Ultra-rare sarcomas (URS) comprise a group of orphan diseases with an incidence of≤ 1/1,000,000 people per year. We aimed to assess clinically actionable genomic alterations in URS. Experimental Design: Data were extracted from the GENIE database …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Song et al. | A new approach to predict progression-free survival in stage IV EGFR-mutant NSCLC patients with EGFR-TKI therapy | |
| Dummer et al. | Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial | |
| Powles et al. | Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial | |
| Pender et al. | Genome and transcriptome biomarkers of response to immune checkpoint inhibitors in advanced solid tumors | |
| Taieb et al. | Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial | |
| Schwaederle et al. | Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing | |
| Morgan et al. | The genomic landscape of breast cancer brain metastases: a systematic review | |
| Li et al. | Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection | |
| Qu et al. | The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer | |
| Hodi et al. | Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin | |
| Ricciuti et al. | Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer | |
| Serrano et al. | Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine kinase inhibitor refractory gastrointestinal stromal tumors | |
| Marcon et al. | Comprehensive genomic analysis of translocation renal cell carcinoma reveals copy-number variations as drivers of disease progression | |
| Hemming et al. | Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1 | |
| EP3392348A2 (en) | Method for selecting personalized tri-therapy for cancer treatment | |
| Carethers | DNA testing and molecular screening for colon cancer | |
| Shimada et al. | Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer | |
| Bueno et al. | Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (alliance) | |
| Slotkin et al. | Comprehensive molecular profiling of desmoplastic small round cell tumor | |
| Schaufler et al. | Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer | |
| Nazha et al. | Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune‐checkpoint inhibitor‐related biomarkers | |
| Rotow et al. | Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers | |
| Feng et al. | Therapeutic implication of genomic landscape of adult metastatic sarcoma | |
| Murugesan et al. | Genomic profiling of combined hepatocellular cholangiocarcinoma reveals genomics similar to either hepatocellular carcinoma or cholangiocarcinoma | |
| Tsuji et al. | Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer |